CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...

Regulatory approvals for Crispr Therapeutics' CASGEVY program are increasing, expanding the potential market for the treatment. Government support, including public funds, is likely to be available ...

Dyadic International Inc (DYAI) marks a pivotal shift towards commercialization with strategic partnerships and technological advancements, despite facing revenue and net loss hurdles.

Q3 2025 Management View President & COO Joseph Hazelton highlighted a pivotal shift, stating Dyadic is now operating as a “commercially focused biotechnology company with a growing portfolio of ...

Completed strategic pivot from R&D focus to commercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned ...

Crispr stock reversed lower Monday, while Intellia stock surged, on promising updates for their gene-editing efforts.

Crispr Therapeutics’ first-quarter results align with our expectations, and its early-stage pipeline candidates are advancing in clinical trials. We continue to expect 2024 will be a pivotal year as ...

BASEL, Switzerland, CAMBRIDGE, Mass., and GAITHERSBURG, Md., March 14, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative ...

Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its ...

CRISPR's shares have started to climb this year. The company’s lead therapy, exa-cel, is expected to have its Biologics License Application submission soon. The FDA could approve exa-cel later this ...